In a landmark Phase 2 trial published in the New England Journal of Medicine, participants receiving the 12 mg dose experienced mean weight loss of 24.2% at 48 weeks, significantly exceeding results from earlier GLP-1 or dual-agonist therapies
Whether youre a slow responder, stuck at a plateau, or want to optimize your results, youll find real answers here
The ER thresholds and warning signs are the same regardless of diabetes status
Orna Fisher , a board-certified plastic surgeon with expertise in post-GLP-1 skin surgery, post-bariatric plastic surgery, and skin removal after weight loss
Lower doses mean less medication drawn per injection, which means each vial lasts longer in terms of dose count, but the BUD does not change